Vanguard Group Inc An2 Therapeutics, Inc. Put Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.38 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.37 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$3.01 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.69 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.65 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $42.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...